Morgan Stanley Travere Therapeutics, Inc. Transaction History
Morgan Stanley
- $1.36 Trillion
- Q1 2025
A detailed history of Morgan Stanley transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,642,061 shares of TVTX stock, worth $25.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,642,061
Previous 1,650,603
0.52%
Holding current value
$25.2 Million
Previous $28.8 Million
2.34%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding TVTX
# of Institutions
239Shares Held
99.9MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$136 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$117 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$115 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$76.9 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$73.6 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $984M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...